top of page
Search
    • Oct 15, 2021

NuvOx Pharma Receives Phase I STTR Grant from NINDS for Preclinical Studies in Stroke

Tucson, AZ, October 12, 2021 --(PR.com)-- NuvOx Pharma, a Tucson based biotechnology company, has received a $478,000 NIH Phase I Small Business Technology Transfer (STTR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) under award number R41NS124450. Click here to read more.

Recent Posts

See All

NuvOx Receives SPAN Grant to Conduct Late-stage Preclinical Studies of Putative Neuroprotectants Combined with Reperfusion Tucson, AZ, April 17th, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotec

bottom of page